RMX Biopharma Co., Ltd (Headquarters in Hangzhou, China, CEO: RuiPing Dong, RMX), which licensed AskAt’s EP4 antagonist AAT-007 (generic name: grapiprant) for pain indications in People’s Republic of China (China), submitted an investigational new drug (IND) application to the State Food and Drug Administration and Supervision Authority of China (CFDA) and the IND has been accepted.

With the CFDA’s acceptance of the AAT-007 IND, human trials can now be initiated for the first time in China.   RMX will continue to develop AAT-007 for a new chronic pain therapy in China based on the pharmacological efficacies and superior safety previously demonstrated in preclinical studies as well as in human clinical trials in the USA.